TNT Study: Baseline Characteristics of the Patients

Slides:

Advertisements

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Advertisements

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

Managing the late consequences of CHD: What is the evidence for lipid management Prof Philip Barter The Heart Research Institute Sydney, Australia Slides.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Journal Club 亀田メディカルセンター糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田昌文 Matsuda, Masafumi 2007 年 11 月 1 日 8:20-8:50 B 棟８階カンファレンス室.

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

Amarenco P, Labreuche J. Lancet Neurol 2009;8:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

NICE –CG 181 Continuum of CVD Risk and its treatment

The SPRINT Research Group

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Baseline Characteristics of the Patients Part I

AIM HIGH Niacin plus Statin to prevent vascular events

HDL cholesterol and cardiovascular risk Epidemiological evidence

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

HDL cholesterol and cardiovascular risk

FATS- Familial Atherosclerosis Treatment Study

TNT: Baseline and final LDL cholesterol levels

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

PCSK9 Inhibitors Post-CVOTs

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Management of hypertension in patients with chronic kidney disease

PCSK9 Inhibitors and Cardiovascular Outcomes

Five Things You Need to Know About Secondary Prevention Post-ACS

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Lipid Clinic Challenge

Aspirin and Cardioprevention in 2018

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Statins, Obesity, and Hyperlipidemia

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Potential mechanisms whereby statins may reduce the risk of stroke

Enrollment and Outcomes

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

Baseline Characteristics of the Subjects

New Lipid-Lowering Therapies

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics of the Subjects*

Women’s Health Study: Baseline Characteristics Part 1

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Baseline Characteristics of the Patients – Part I

Baseline Characteristics of the Patients - Part I

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

The ACCORD Study Group. NEJM 2010; Epub March 14

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

TNT diabetes analysis: Baseline and final LDL cholesterol levels

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

TNT Study: Baseline Characteristics of the Patients JC LaRosa, N Engl J Med 2005; 352

TNT Study: Mean Lipid Levels during the Study JC LaRosa, N Engl J Med 2005; 352

TNT Study: Cumulative Incidence of a First Major Cardiovascular Endpoint JC LaRosa, N Engl J Med 2005; 352

TNT Study: Estimated Hazard Ratio for the Components of the Primary and Secondary Efficacy Outcomes JC LaRosa, N Engl J Med 2005; 352

TNT Study: Characteristics of Five Patients with Rhabdomyolysis JC LaRosa, N Engl J Med 2005; 352

TNT Study: Event Rates Plotted against LDL Cholesterol Levels during Statin Therapy in Secondary-Prevention Studies JC LaRosa, N Engl J Med 2005; 352